米索前列醇在子宫内膜不典型增生中的治疗价值

目的观察米索前列醇在子宫内膜不典型增生患者中的治疗效果和临床应用价值。方法将收治的82例自愿接受保守治疗的子宫内膜不典型增生的病人随机分为实验组(41例)和对照组(41例)。实验组应用米索前列醇联合米非司酮连续治疗6月,对照组只应用米非司酮治疗6个月。完成治疗后对两组患者的效果进行评价。结果实验组患者中27例为显效,12例有效,2例无效,无恶化病例。对照组患者中20例显效,8例有效,11例无效,无恶化病例。实验组的总有效率为95.1%,对照组的总有效率为68.3%,两组有明显统计学差异(P<0.05)。结论米索前列醇联合米非司酮治疗子宫内膜不典型增生疗效明显,相较单独使用米非司酮治疗具有明显优势,值得在临床推广使用。

Objective To observe the therapeutic value of misoprostol in the atypical endometrial hyperplasia.Methods 82 patients with endometrial atypical hyperplasia were divided randomly into treatment group（41 cases） and control group（41 cases）.Patients in the treatment group took misoprostol together with mifepristone continually for 6 months.Patients in the control group took mifepristone individually for 6 months.Results 27 cases in the treatment group were pathology identified powerfully,12 cases were effective,2 cases were invalid and there were no dead cases.20 cases in the control group were pathology identified powerfully,8 cases were effective,11 cases were invalid and there were no dead cases.The total effective rate of treatment group was 95.1% while the control group was 68.3%.The differences between the two groups was statistically significant（P0.05）.Conclusion The effect of misoprostol together with misfepristone is superior to the misfepristone alone and the misoprostol has a good safety and clinical value.It is recommended to be used in the therapy of atypical endometrial hyperplasia.